PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results
Demonstrate Safety and Efficacy at Once-Weekly Dosing
... Diabetes Patients -
MONTREAL, March 26 /CNW/ -
conjuchem Biotechnologies Inc.
(TSX:CJB) today announced p...d effective in lowering blood glucose levels."
conjuchem intends to submit the study results for presentati...7.
In conjunction with the multi-dose results,
conjuchem also
reported that ongoing product development p...
ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin
Conjugate Data Presented at American Diabetes Association Annual
Meeting
... MONTREAL, June 19 /CNW/ -
conjuchem Biotechnologies (TSX:CJB)
today announced that da... a small volume with a small gauge
needle.
About
conjuchem
ConjuChem, developer of next generation medicine...ion: Lennie Ryer, CA, Vice President
Finance, CFO,
conjuchem Biotechnologies Inc., (514) 844-5558 ext
224,
ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4
...AGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ -
conjuchem Biotechnologies Inc. (TSX:CJB) and Novozymes Bioph...TM):Exendin-4 increases. The Agreement also allows
conjuchem to fully assign all rights to a PC-DAC(TM):Exendin-4 licensee.
In a separate Agreement,
conjuchem and Novozymes Biopharma entered into a Pipeline Pr...
ConjuChem Provides Development Update
...sults - MONTREAL, Nov. 5 /PRNewswire-FirstCall/ -
conjuchem Biotechnologies
Inc. (TSX:CJB) announced today tha...umin(R), provided
by Novozymes Biopharma).
About
conjuchem Biotechnologies
conjuchem Biotechnologies, developer of next generation medi...
Aegera Therapeutics welcomes two experienced executives to its board of directors
...h Capital Management - Mr. Joseph Regan, B.Sc., MBA, Vice President, GrowthWorks Capital - Mr. Lennie Ryer, B. Comm, CA, CFE, CFO and VP Finance,
conjuchem The detailed biographies of Mr. Curnock Cook, Mr. Littlejohn and all of
Aegera's Board Members can be viewed at http://www.aegera.com
About Aeger...